Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Peter M. Hickey"'
Publikováno v:
Frontiers in Medicine, Vol 5 (2018)
Pulmonary arterial hypertension (PAH) develops in 7–12% of patients with systemic sclerosis (SSc) and is associated with a 3 year survival of 52%. Early detection by screening is therefore recommended for all patients with SSc. Historically, screen
Externí odkaz:
https://doaj.org/article/a47624695b9745d38e275a4d71a14b8d
Autor:
Josephine Pickworth, Alexander Rothman, James Iremonger, Helen Casbolt, Kay Hopkinson, Peter M. Hickey, Santhi Gladson, Sheila Shay, Nicholas W. Morrell, Sheila E. Francis, James D. West, Allan Lawrie
Publikováno v:
Pulmonary Circulation, Vol 7 (2017)
Bone morphogenetic protein receptor type 2 (BMPR2) mutations are present in patients with heritable and idiopathic pulmonary arterial hypertension (PAH). Circulating levels of interleukin-1 (IL-1) are raised in patients and animal models. Whether int
Externí odkaz:
https://doaj.org/article/269ad62df14a47e7a87b0dca7a1a883a
Autor:
Robin Condliffe, Laura C. Saunders, Samer Alabed, Faisal Alandejani, Alistair W Macdonald, Marcella Cogliano, Peter M. Hickey, Anthony Cahn, Lindsay Kendall, Matthew Austin, Yousef Shahin, Christopher S. Johns, Allan Lawrie, Pankaj Garg, David G. Kiely, Frederick J. Wilson, Paul Hughes, J Pickworth, David Capener, Alexander M.K. Rothman, Andrew J. Swift, Jim M. Wild, Charlotte Oram
Publikováno v:
Thorax
End points that are repeatable and sensitive to change are important in pulmonary arterial hypertension (PAH) for clinical practice and trials of new therapies. In 42 patients with PAH, test–retest repeatability was assessed using the intraclass co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926c752322a76f611b6aa406841294f4
https://doi.org/10.1136/thoraxjnl-2020-216078
https://doi.org/10.1136/thoraxjnl-2020-216078
Autor:
Peter M. Hickey, Robert A. Lewis, Judith Hurdman, A. A. Roger Thompson, Marcella Cogliano, Euan Tubman, Christopher S. Johns, Robin Condliffe, Catherine Billings, Iain Armstrong, Jennifer Middleton, Peter J. Laud, Charlie Elliot, Athanasios Charalampopoulos, David G. Kiely, Ian Sabroe, Kathleen Baster, Alexander M.K. Rothman, Andrew J. Swift, Jim M. Wild, Neil Hamilton, Allan Lawrie, David Capener
Publikováno v:
American Journal of Respiratory and Critical Care Medicine
Rationale: Pulmonary arterial hypertension (PAH) is a life-shortening condition. The European Society of Cardiology and European Respiratory Society and the REVEAL (North American Registry to Evaluate Early and Long-Term PAH Disease Management) risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d437d153dde8f7d824c64f4bec0c24eb
https://doi.org/10.1164/rccm.201909-1771oc
https://doi.org/10.1164/rccm.201909-1771oc
Autor:
Sheila Shay, James Iremonger, Peter M. Hickey, Josephine A. Pickworth, Helen Casbolt, Allan Lawrie, Nicholas W. Morrell, Kay Hopkinson, Sheila E. Francis, James West, Alexander M.K. Rothman, Santhi Gladson
Publikováno v:
Pulmonary Circulation
Pulmonary Circulation, Vol 7 (2017)
Pulmonary Circulation, Vol 7 (2017)
Background: Bone morphogenetic protein receptor type 2 (BMPR2) mutations are present in patients with heritable and idiopathic pulmonary arterial hypertension (PAH). Circulating levels of Interleukin-1 (IL-1) are raised in patients and animal models.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f294bd24312adfdac2cbdd010d912f
http://europepmc.org/articles/PMC5703124
http://europepmc.org/articles/PMC5703124
Autor:
Allan Lawrie, Jim M. Wild, Matthew Austin, Marcella Cogliano, Tony Kahn, Dave Capener, Peter M. Hickey, Fred Wilson, Robin Condliffe, Charlotte Oram, Alexander M.K. Rothman, Andrew J. Swift, Lindsay Kendall, Pankaj Garg, David G. Kiely, Christopher S. Johns, J Pickworth
Publikováno v:
Pulmonary hypertension.
Introduction: For clinical trials it is important to know the repeatability and sensitivity to change of study end-points. The aim of this study was to compare non-invasive candidate end-points in patients with pulmonary arterial hypertension (PAH).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f6176abcb9600c4f9f5aed2e4f3fa1
https://doi.org/10.1183/13993003.congress-2019.oa496
https://doi.org/10.1183/13993003.congress-2019.oa496
Autor:
Peter M. Hickey, Allan Lawrie, Vidhya Balasubramanian, Haley Hedlin, Robin Condliffe, Lisa K. Blum, William H. Robinson, Andrew Hsi, Marlene Rabinovitch, Francois Haddad, Roham T. Zamanian, Mark R. Nicolls, Purvesh Khatri, Andrew J. Sweatt
Publikováno v:
Circulation research. 124(6)
Rationale: Accumulating evidence implicates inflammation in pulmonary arterial hypertension (PAH) and therapies targeting immunity are under investigation, although it remains unknown if distinct immune phenotypes exist. Objective: Identify PAH immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87cd7bb4bed5d7e31b77b4086c47950b
https://pubmed.ncbi.nlm.nih.gov/30870130
https://pubmed.ncbi.nlm.nih.gov/30870130
Autor:
Sébastien Roux, Allan Lawrie, Martin Doelberg, Oliver Distler, Jeremy Cruz, Yasmina Bauer, Simon de Bernard, Daniel W. Rosenberg, Oliver Nayler, Karri Ballard, Peter Cornelisse, Harbajan Chadha-Boreham, Peter M. Hickey
Publikováno v:
European Respiratory Journal. 57:2002591
Pulmonary arterial hypertension (PAH) is a devastating complication of systemic sclerosis (SSc). Screening for PAH in SSc has increased detection, allowed early treatment for PAH and improved patient outcomes. Blood-based biomarkers that reliably ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c2a064760a12f3295778ca9a11d9ec0
https://doi.org/10.1183/13993003.02591-2020
https://doi.org/10.1183/13993003.02591-2020
Autor:
Robin Condliffe, Robert A. Lewis, Athanasios Charalampopoulos, Charlie Elliot, David G. Kiely, Ian Sabroe, Charlotte Durrington, Peter M. Hickey
Publikováno v:
Frontiers in Medicine
Frontiers in Medicine, Vol 5 (2018)
Frontiers in Medicine, Vol 5 (2018)
Pulmonary hypertension due to left heart disease (PH-LHD) is the most common type of pulmonary hypertension, although an accurate prevalence is challenging. PH-LHD includes PH due to systolic or diastolic left ventricular dysfunction, mitral or aorti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a484a8d9cad432cc9cbe2916503cb52
Publikováno v:
Foundations of Respiratory Medicine ISBN: 9783319941257
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1e31e176d287d7008de3cd7d53b6c63
https://doi.org/10.1007/978-3-319-94127-1_19
https://doi.org/10.1007/978-3-319-94127-1_19